JP2022551844A5 - - Google Patents
Info
- Publication number
- JP2022551844A5 JP2022551844A5 JP2022520676A JP2022520676A JP2022551844A5 JP 2022551844 A5 JP2022551844 A5 JP 2022551844A5 JP 2022520676 A JP2022520676 A JP 2022520676A JP 2022520676 A JP2022520676 A JP 2022520676A JP 2022551844 A5 JP2022551844 A5 JP 2022551844A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable domain
- abpc
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025156043A JP2025181917A (ja) | 2019-10-04 | 2025-09-19 | 抗原結合タンパク質構築物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910935P | 2019-10-04 | 2019-10-04 | |
| US62/910,935 | 2019-10-04 | ||
| PCT/US2020/053910 WO2021067673A1 (en) | 2019-10-04 | 2020-10-02 | Antigen-binding protein constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156043A Division JP2025181917A (ja) | 2019-10-04 | 2025-09-19 | 抗原結合タンパク質構築物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551844A JP2022551844A (ja) | 2022-12-14 |
| JP2022551844A5 true JP2022551844A5 (enExample) | 2023-09-13 |
| JP7818509B2 JP7818509B2 (ja) | 2026-02-20 |
Family
ID=73014627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520676A Active JP7818509B2 (ja) | 2019-10-04 | 2020-10-02 | 抗原結合タンパク質構築物およびその使用 |
| JP2025156043A Pending JP2025181917A (ja) | 2019-10-04 | 2025-09-19 | 抗原結合タンパク質構築物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156043A Pending JP2025181917A (ja) | 2019-10-04 | 2025-09-19 | 抗原結合タンパク質構築物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220348679A1 (enExample) |
| EP (1) | EP4037775A1 (enExample) |
| JP (2) | JP7818509B2 (enExample) |
| CN (2) | CN120204419A (enExample) |
| AU (1) | AU2020357980A1 (enExample) |
| CA (1) | CA3157028A1 (enExample) |
| IL (1) | IL291904A (enExample) |
| WO (1) | WO2021067673A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2026093513A1 (en) | 2024-10-31 | 2026-05-07 | Sotio Biotech A.S. | Anti-lrrc15 antibodies and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050239700A1 (en) * | 2003-10-14 | 2005-10-27 | Biogen Idec Inc. | Treatment of cancer using antibodies to LRRC15 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| MX2012002651A (es) | 2009-09-01 | 2012-05-22 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| NZ602220A (en) * | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| JP2019501124A (ja) * | 2015-11-30 | 2019-01-17 | アッヴィ・インコーポレイテッド | 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法 |
| EP3383909B1 (en) * | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| WO2019075392A1 (en) * | 2017-10-12 | 2019-04-18 | Inevation Llc | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF |
-
2020
- 2020-10-02 JP JP2022520676A patent/JP7818509B2/ja active Active
- 2020-10-02 CN CN202510265904.5A patent/CN120204419A/zh active Pending
- 2020-10-02 WO PCT/US2020/053910 patent/WO2021067673A1/en not_active Ceased
- 2020-10-02 CN CN202080081551.9A patent/CN114728175A/zh active Pending
- 2020-10-02 AU AU2020357980A patent/AU2020357980A1/en active Pending
- 2020-10-02 EP EP20797282.9A patent/EP4037775A1/en active Pending
- 2020-10-02 US US17/765,153 patent/US20220348679A1/en active Pending
- 2020-10-02 CA CA3157028A patent/CA3157028A1/en active Pending
-
2022
- 2022-04-03 IL IL291904A patent/IL291904A/en unknown
-
2025
- 2025-09-19 JP JP2025156043A patent/JP2025181917A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022543771A5 (enExample) | ||
| JP6817492B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| JP6670275B2 (ja) | 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体 | |
| CN102741282B (zh) | 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 | |
| JP6865585B2 (ja) | 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| JP7579990B2 (ja) | 抗ネクチン－４抗体およびその使用 | |
| CN114014932A (zh) | 滋养层细胞表面抗原2(trop2)特异性抗体 | |
| TW201938587A (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| CN112955548A (zh) | 叶酸受体α特异性抗体 | |
| US20100092455A1 (en) | Novel anti-proliferation antibodies | |
| CN107074949B (zh) | 抗神经酰胺抗体 | |
| CN104797600A (zh) | 能够特异性识别转铁蛋白受体的抗体 | |
| JP2022534808A5 (enExample) | ||
| CN108025093A (zh) | 用于在治疗癌症中使用的放射性标记的抗体片段 | |
| TW201526914A (zh) | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 | |
| JP2022535452A5 (enExample) | ||
| JP6640232B2 (ja) | クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体 | |
| CN111848805B (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
| CN106164094B (zh) | 双特异性抗原结合多肽 | |
| KR20240021294A (ko) | 항-her3 항체, 이를 함유하는 항체-약물 접합체 및 그 용도 | |
| JP2021516670A (ja) | 抗ｔｒａｉｌｒ２抗体−毒素−複合体およびその抗腫瘍治療における薬物用途 | |
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| JP2024535851A5 (enExample) | ||
| US20250197501A1 (en) | Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers |